Prof. Zander
Prof. Dr. med. Dr. h.c. Axel R. Zander
Telefon: (040) 7410 - 54850
Telefax: (040) 7410 - 53795
E-Mail: zander(at)uke.uni-hamburg.de
Academic title (Akademischer Titel):
Prof. Dr. med. Dr. h. c.
Date of birth (Geburtsdatum):
October 22nd 1943
Nationality (Nationalität):
German
Present position (Gegenwärtige Position):
Chief of Stem Cell Transplantation Center, University Medical Center Hamburg-Eppendorf / Germany (since 1990)
Professional qualifications (Berufliche Qualifikation mit Angabe von erworbenem Grad, Datum und Universität):
1976 – 1977
Assistant Professor of Medicine, Assistant Internist
University of Illinois, Department of Development Therapeutics
1977 – 1981
Assistant Professor
MD Anderson Hospital and Tumor Institute, Houston, Texas
1981 – 1985
Associate Professor
MD Anderson Hospital and Tumor Institute, Houston, Texas
1985 – 1989
Chief
Section of Bone Marrow Transplantation, Department of Medicine, Pacific Presbyterian Medical Center, San Francisco, CA
1985 – 1989
Senior Associate Member
Medical Research Institute of San Francisco, CA
1990 -
Professor of Medicine
Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf / Germany
1997
Doctor honoris causa
St. Petersburg State I. Pavlov Medical University / Russia
Previous appointments (Frühere Positionen):
1963 – 1968
Medical School, Munich, Lübeck
02/1969 – 06/1970
Medizinalassistentenzeit (Internship)
Rittberg Hospital Berlin
- Internal Medicine
- Gynaecology
Rotkreuzkrankenhaus Drontheimer Str., Berlin
- Surgery
1970 – 1971
Internship
Westsuburban Hospital, Oak Park, Illinois
1971 – 1973
Resident in Internal Medicine
Westsuburban Hospital, Oak Park, Illinois
1973 – 1976
Fellowship in Hematology / Oncology
University of Illinois, Chicago
1976 – 1977
Assistant Professor of Medicine
Assistant Internist
University of Illinois,
Department of Development Therapeutics
1977 – 1981
Assistant Professor
MD Anderson Hospital and Tumor Institute, Houston, Texas
1981 – 1985
Associate Professor
MD Anderson Hospital and Tumor Institute, Houston, Texas
1985 – 1989
Chief
Section of Bone Marrow Transplantation, Department of Medicine, Pacific Presbyterian Medical Center, San Francisco, CA
1985 – 1989
Senior Associate Member
Medical Research Institute of San Francisco, CA
1990 -
Professor of Medicine
Clinic for Stem Cell Transplantation,
University Medical Center Hamburg-Eppendorf / Germany
Summary of teaching and research experience (Erfahrungen in Lehre und Forschung):
Teaching and research experience since 1975, University of Illinois (Assistant Professor)
Membership of medical scientific societies (Mitgliedschaft in medizinisch-wissenschaftlichen Gesellschaften):
Aktuelleste Veröffentlichungen finden Sie auch unter: Zander, Axel
(Stand Januar 2009)
1. Rischer J, Scherwath A, Zander AR, Koch U, Schulz-Kindermann F. Sleep disturbances and emotional distress in the acute course of hematopoietic stem cell transplantation. Bone Marrow Transplant. 2009 Jan 19. [Epub ahead of print].
2. Bacher U, Badbaran A, Fehse B, Zabelina T, Zander AR, Kröger N. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol. 2009 Jan;37(1):135-42.
3. Ocheni S, Kröger N, Zabelina T, Zander AR, Bacher U. Outcome of allo-SCT for chronic myelomonocyte leukemia. Bone Marrow Transplant. 2008 Nov 10. [Epub ahead of print] No abstract available.
4. Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008 Oct 15;112(8):3500-7. Epub 2008 Jul 29.
5. Ayuk F, Perez-Simon JA, Shimoni A, Sureda A, Zabelina T, Schwerdtfeger R, Martino R, Sayer HG, Alegre A, Lahuerta J-J, Atanackovic D, Wolschke C, Nagler A, Zander AR, San Miguel JF, Kröger N. Clinical impact of human target Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica. 2008 Sep;93(9):1343-50. [Epub. July 18, 2008]
6. Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, Erttmann R, Kröger N, Zander AR. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Aug;14(8):913-9.
7. Tichelli A, Passweg J, Wójcik D, Rovó A, Harousseau JL, Masszi T, Zander A, Békássy A, Crawley C, Arat M, Sica S, Lutz P, Socié G; EBMT Late Effects Working Party. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008 Aug;93(8):1203-10. Epub 2008 Jun 12.
8. Bacher U, Zander AR, Haferlach T, Schnittger S, Fehse B, Kröger N. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant. 2008 Jun 30. [Epub ahead of print]
9. Ocheni S, Kroeger N, Zabelina T, Sobottka I, Ayuk F, Wolschke C, Muth A, Lellek H, Petersen L, Erttmann R, Kabisch H, Zander AR, Bacher U. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant. 2008 Jun 2. [Epub ahead of print]
10. Magin AS, Koerfer NR, Partenheimer H, Lange C, Zander A, Noll T. Primary cells as feeder cells for coculture expansion of human hematopoietic stem cells from umbilical cord blood. A comparative study. Stem Cells Dev. 2008 May 9. [Epub ahead of print]
11. Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kröger N, Zander AR. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp Hematol. 2008 May 2. [Epub ahead of print]
12. Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-Simón JA, Gutierrez NC, Bethge W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Penas EM, Dierlamm J, Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, San Miguel J, Nagler A, Kröger N. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2008 Jun;22(6):1250-5. Epub 2008 Apr 17. Erratum in: Leukemia. 2008 Oct;22(10):1974. Simon-Perez, J-A [corrected to Pérez-Simón, J-A]; Miguel, J S [corrected to San Miguel, J].
13. Lioznov M, Dellbrügger C, Sputtek A, Fehse B, Kröger N, Zander AR. Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM. Bone Marrow Transplant. 2008 Apr 7. [Epub ahead of print]
14. Zander AR, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, Metzner B, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Kreienberg R, Schumacher M, Jonat W. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up. Ann Oncol. 2008 Jun;19(6):1082-9. Epub 2008 Feb 27.
15. Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander AR, Fehse B, Bokemeyer C, Kroger N. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica. 2008 Mar;93(3):423-30. Epub 2008 Feb 20.
16. Lioznov M, Badbaran A, Fehse B, Bacher U, Zander AR, Kröger NM. Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques. Bone Marrow Transplant. 2008 May;41(10):913-6. Epub 2008 Feb 11. No abstract available.
17. Ayuk FA, Atassi N, Schuch G, Mina S, Fang L, Bokemeyer C, Fehse B, Zander AR, Kröger N. Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia. Leuk Res. 2008 Aug;32(8):1200-6. Epub 2008 Feb 4.
18. Goekkurt E, Stoehlmacher J, Stueber C, Wolschke C, Eiermann T, Iacobelli S, Zander AR, Ehninger G, Kröger N. Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. Anticancer Res. 2007 Nov-Dec;27(6C):4377-80.
19. Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, Bethge W, Schubert J, de Witte T, Kvasnicka HM; MDS-Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol. 2007 Nov;35(11):1719-22.
20. Vavilov VN, Zander AR, Afanasiev BV. [Recovery of peripheral blood lymphocytes in patients with hematological diseases after allogenic non-relative transplantation of hemopoietic stem cells] Ter Arkh. 2007;79(7):44-7. Russian.
21. Ehlert K, Frosch M, Fehse N, Zander A, Roth J, Vormoor J. Farber disease: clinical presentation, pathogenesis and a new approach to treatment. Pediatr Rheumatol Online J. 2007 Jun 29;5:15.
22. Ittrich H, Lange C, Togel F, Zander AR, Dahnke H, Westenfelder C, Adam G, Nolte-Ernsting C. In vivo magnetic resonance imaging of iron oxide-labeled, arterially-injected mesenchymal stem cells in kidneys of rats with acute ischemic kidney injury: Detection and monitoring at 3T. J. Magn. Reson. Imaging. 2007 Jun;25(6):1179-91.
23. Lange C, Cakiroglu F, Spiess AN, Cappallo-Obermann H, Dierlamm J, Zander AR. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenrative medicine. J. Cell Physiology. 2007 Oct;213(1);18-26
24. Schulz-Kindermann F, Mehnert A, Scherwath A, Schirmer L, Schleimer B, Zander AR, Koch U. Cognitive function in acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies. Bone Marrow Transplantation 2007 Jun;39(12:789-99)
25. Bacher U, Zander AR. Long-term safety of filgratsim (rhG-CSF) administration: application of haematopoietic growth factors in healthy individuals. British Journal of haematology 2007 Apr;137(1):78-9;author reply 79-80.
26. Weissinger EM, Schiffer E, Hertenstein B, Ferrara JL, Holler E, Stadler M, Kolb HJ, Zander A, Zürbig P, Kellmann M, Ganser A. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2007 Jun 15;109(12):5511-9. Epub 2007 Mar 5.
27. Mehnert A, Scherwath A, Schirmer L, Schleimer B, Petersen C, Schulz-Kindermann F, Zander AR, Koch U. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns. 2007 Apr;66(1):108-18. Epub 2007 Feb 21.
28. Mosbauer U, Ayuk F, Schieder H, Lioznov M, Zander AR, Kroger N. Monitoring serum free light chains in patients with multiple myeloma who achieved nagative immunofixation after allogeneic stem cell transplantation. Haematologica. 2007 Feb;92(2):275-6.
29. Thiele J, Varus E, Siebolts U, Kvasnicka HM, Wickenhauser C, Metz KA, Beelen DW, Ditschkowski M, Zander A, Kröger N. Dualism of mixed chimerism between hematopoiesis and stroma in chronic idiopathic myelofibrosis after allogeneic stem cell transplantation. Histol Histopathol. 2007 Apr;22(4):365-72.
30. Fang L, Lange C, Engel M, Zander AR, Fehse B. Sensitive Balance of Suppressing and Activating Effects of Mesenchymal Stem Cells on T-cell Proliferation. Transplantation 2006, Vol 82, No 10, November 27. 1370-3.
31. Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, Ayuk F, Dahlke J, Eiermann T, Zander A. Low number of donor activating killer immunoglobulin-like receptors [KIR] genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation. 2006 Oct 27;82(8):1024-30.
32. Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C, Dierlamm J, Ritter G, Eiermann T, Hossfeld DK, Zander AR, Jungbluth AA, Old LJ, Bokemeyer C, Kroger N. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood. 2007 Feb 1;109(3):1103-12.
33. Kroger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhauser M, Reiter A, Zabelina T, Zander AR, Fehse B. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in ptients with myelofibrosis. Blood 2007 Feb 1;109(3):1316-21.
34. Fiegel HC, Lange C, Kneser U, Lambrecht W, Zander AR, Rogiers X, Kluth D. Fetal and adult liver stem cells for liver regeneration and tissue engineering. Journal of Cellular and Molecular Medicine. Vol 10, No 3, 2006. 577-587
35. Oyekunle A, Koehl U, Schieder H, Ayuk F, Renges H, Fehse N, Zabelina T, Fehse B, Klingbiehl T, Sputtek A, Zander AR, Kroger N. CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation. Cytotherapy. 2006;8(4):375-80.
36. Kroger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann HW, Meier CR, Lohrmann HP, Ruffert U, Hanel M, Bodenstein H, Neubauer A, Ehninger G, Wolf HH, Kolbe K, Burock K, Zander AR, Nitz U. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol. 2006 Aug 20;24(24):3919-26.
37. Giordano FA, Fehse B, Hotz-Wagenblatt a, Jonnakuty S, Val CD, Appelt JU, Nagy KZ, Kuehlcke K, Naundorf S, Zander AR, Zeller WJ, Ho AD, Fruehauf S, Laufs S. Retroviral vector insertions in T-Lymphocytes used for suicide gene groups with specific molecular functions. BMT. 2006 Aug;38(3):229-35.
38. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho a, Mufti GJ, Kroger N, Zander AR, Heim D, Paluszewska M, Selleslag D, Steinerova K, Ljungman P, Cesaro S, Nihtinen A, Cordonnier C, Vasquez L, Lopez-Duarte M, Lopez J, Cabrera R, Rovira M, Neuburger S, Cornely O, Hunter AE, Marr KA, Dornbusch HJ, Einsele H. Impact of the intensity of the pre-transplant conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the infectious diseases working party of the european group for blood and marrow transplantation.
Blood. 2006 Nov 1;108(9):2928-36.
39. Kröger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H, Zander A. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol. 2006 Jun;34(6):770-5.
40. Schade UM, Nehmann N, Horny HP, Prehm P, Delpech B, Kruger WH, Zander AR, Schumacher U. Hyaluronate and its receptors in bone marrow.
Acta Histochem. 2006;108(2):141-7. Epub 2006 May 19.
41. Lange C, Bruns H, Kluth D, Zander AR, Fiegel HC. Hepatocytic differentiation of mesenchymal stem cells in cocultures with fetal liver cells. World J Gastroenterol. 2006 Apr 21;12(15):2394-7.
42. Kröger N, Zagrivnaja M, Schwartz S, Badbaran A, Zabelina T, Lioznov M, Ayuk F, Zander A, Fehse B. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. Exp Hematol. 2006 May;34(5):688-94.
43. Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant. 2006 Feb;37(4):339-44.
44. Kroger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Loning T. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res. 2006 Jan 1;12(1):159-68.
45. Scherwath A, Mehnert A, Schleimer B, Schirmer L, Fehlauer F, Kreienberg R, Metzner B, Thiel E, Zander AR, Schulz-Kindermann F, Koch U. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol. 2006 Mar;17(3):415-23. Epub 2005 Dec 15.
46. Bornhauser M, Kroger N, Schwerdtfeger R, Schafer-Eckart K, Sayer HG, Scgeid C, Stelljes M, Kienast J, Mundhenk P, Fruehauf S, Kiehl MG, Wandt H, Theuser C, Ehninger G, Zander AR; Cooperative German Transplant Studyy Group. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Eur J Haematol. 2006 Jan;76(1):9-17.
47. Ayuk FA, Fang L, Fehse B, Zander AR, Kroger N. Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. Exp Hematol. 2005 Dec;33(12):1531-6.
48. Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T; Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2006 Jan;37(2):183-9.
49. Dahlke, J, Kroger N, Zabelina T, Ayuk F, Fehse N, Wolschke C, Waschke O, Schieder H, Renges H, Kruger W, Kruell A, Hinke A, Erttmann R, Kabisch H, Zander AR. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant. 2006 Jan;37(2):155-63.
50. Zander AR, Kroger N. High-dose therapy for breast cancer - a case of suspended animation. Acta Haematol. 2005;114(4):248-54. Review.
51. Oyekunle AA, Kroger N, Zabelina T, Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander AR. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant. 2006 Jan;37(1):45-50.
52. Lange C, Togel F, Ittrich H, Clayton F, Nolte-Ernsting C, Zander AR, Westenfelder C.
Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int. 2005 Oct;68(4):1613-7.
53. Köger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Löning T. Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer Patients. Clin. Cancer Research 2006;12(1) January 1, 2006: 159-168
54. Gharton G, Iacobelli S, Apperley J, Bandini G, Björkstrand B, Bladé JM, Cavo M, Cornelissen J, Corradini P, Kröger N, Ljungman P, Michallet M, Russell NH, Samson D, Schattenberg A, Sirohi B, Verdonck LF, Volin L, Zander AR and Niederwiser D. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. BMT (2005) 35, 609-617
55. Lange C, Bassler Ph, Lioznov MV, Bruns H, Kluth D, Zander AR, Fiegel HC. Liver-specific gene expression in mesenchymal stem cells is induced by liver cells. World Journal of Gastroenterology 2005;11(29):4497-4504
56. Krause K, Fehse B, Jaquet K, Lange C, Kyriazis K, Boczor S, Zander AR, Kuck, K-H. Analysis of progenitor cell mobilization and erythropoietin plasma levels in patients with acute myocardial infarction. Exp. Clin. Cardiol., Vol. 10, No 2. 2005. 104-107
57. Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI, for the Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Comparison between Antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. British Journal of Haematology, 129, 631-643
58. Thiel J, Kvasnicka HM, Dietrich H, Stein G, Hann M, Kaminski A, Rathjen N, Metz KA, Beelen DW, Ditschkowski M, Zander AR und Kroeger N. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell trasnplantation. Histology and Histopathology (2005) 20: 879-889
59. Lioznov MV, Freiberger P, Kröger N, Zander AR, Fehse B. Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants. BMT (2005) 35, 909-914
60. Krüger W, Rüssmann B, de Wit M, Kröger N, Renges H, Sobottka I, Zander AR. Haemopoietic Cell Transplantation of Patients with a History of Deep or Invasive Fungal infection during Prophylaxis with Liposomal Amphotericin B. Acta Haematologica 2005; 113: 104-108
61. Kröger N, Brand R, van Biezen A, Bron D, Blaise D, Hellström-Lindberg E, Gahrton G, Powles R, Littlewood T, Chapuis B, Zander A, Koza V, Niederwieser D, de Witte T. Stem cell transplantation from identical twins in patients with myelodysplastic syndromes. BMT (2005) 35, 37-43
62. Lange C, Schroeder J, Lioznov MV, Zander AR. High-potential human mesenchymal stem cells. Stem Cells Dev. 2005 Feb;14 (1): 70-80
63. Stute N, Holtz K, Bubenheim M, Lange C, Blake F, Zander AR. Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use. Exp. Hematol. 2004 Dec; 32(12): 1212-25
64. Kröger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N, Fehse N, Waschke O, Fehse B, Kvasnicka HM, Thiele J, Zander AR. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. British Journal of Haematology, 128, 2005. 690-697
65. Kröger N, Perez-Simon J, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR. Relapse to Prior Autograft and Chronic Graft-versus-Host Disease are the Strongest Prognostic Factors for Outcome of Melphalane/Fludarabine-Based Dose-Reduced Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation 10: 698-708 (2004)
66. Ayuk FA, Zander AR, Kröger N. Response to Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusion? By Peggs et al.. Leukemia (2004) 18, 1542-1543
67. Rohde H, Kalitzky M, Kröger N, Scherpe St, Horstkotte MA, Knobloch J, Zander AR, Mack D. Detection of virolence-associated genes not useful for discriminating between invasive and commensal staphylococcus epidermis strains from a bone marrow transplant unit. Journal of Clinical Microbiology, Dec. 2004. pp. 5614-5619
68. Kröger N, Brand R, van Biezen A, Bron D, Blaise D, Hellström-Lindberg E, Gahrton G, Powles R, Littlewood T, Chapuis B, Zander AR, Koza V, Niederwieser D, de Witte T for the Myelodysplastic Syndromes Subcommittee of the Chronic Leukaemia Working Party of the European Blood and Marrow Transplantation Group. Stem cell transplantation from identical twins in patients with myelodysplastic syndromes. Prepublished online in Bone Marrow Transplantation on 8th of November 2004
69. Shimoni A, Kröger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M, Shem-Tov N, Avigdor A, Ben-Bassat I, Zander AR, Nagler A. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age > 55 years) with hematologic malignancies: older age is no longer a contraindication when using a reduced intensity conditioning. Leukemia online prepublished 4th of November 2004. Leukemia 2005 Jan;19(1):7-12
70. Fehse B, Ayuk FA, Kroger N, Fang L, Kuhlcke K, Heinzelmann M, Zabelina T, Fauser AA, Zander AR. Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T-lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells. Blood. 2004 Nov 15;104(10):3408-9
71. Tiercy J-M, Passweg J, van Biezen A, Zander A, Kroger N, Gratwohl A, Chapuis B, Helg C, Brinch L, Cornelissen J, Oudshoorn M, Ruutu T, Volin L, Niederwieser D, Roosnek E. Isolated HLA-C mismatches in unrelated donor transplantation for CML. BMT (2004) August 34: 249-255
72. Kroger N, Shimoni A, Zagrivnaja M, Ayuk F, Lioznov M, Schieder H, Renges H, Fehse B, Zabelina T, Nagler A, Zander AR. Low dose Thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. [Blood. 2004 Aug 3, prepublished online August 3], 2004. Blood, 15. November 2004, Volume 104, Number 10
73. Kiehl M G, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N, Stelljes M, Bornhaeuser M, Martin H, Scheid C, Ganser A, Zander A R, Kienast J, Ehninger G, Hoelzer D, Diehl V, Fauser A A, Ringden O. Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Patients With Acute Lymphoblastic Leukemia: No Difference in Related Compared With Unrelated Transplant in First Complete Remission. JCO, Vol. 22, Number 14, July 15, 2004: 2816-2825
74. Zander AR, Kröger N, Schmoor C, Krüger W, Möbus V, Frickhofen N, Metzner B, Schultze W, Berdel W E, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trümper L, Kreienberg R, Carstensen M, Schmidt EH, Jänicke F, Schumacher M, Jonat W. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. Journal of Clinical Oncology 2004, June 15, Vol 22, Number 12: 2273-2283
75. Loges S, Fehse B, Brockmann MA, Lamszus K, Butzal M, Guckenbiehl M, Schuch G, Ergun S, Fischer U, Zander AR, Hossfeld DK, Fiedler W, Gehling UM. Identification of the adult human hemangioblast. Stem Cells Dev. 2004 Jun;13(3):229-42.
76. Kroger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A, Perez-Simon JA, San Miguel JF, Kiehl M, Fauser A, Schwerdtfeger R, Wandt H, Sayer HG, Myint H, Klingemann H, Zabelina T, Dierlamm J, Hinke A, Zander AR. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood. 2004 Jun 1;103(11):4056-61. Epub 2004 Feb 24.
77. Kroger N, Sonnenberg S, Cortes-Dericks L, Freiberger P, Mollnau H, Zander AR. Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study. Transfusion. 2004 Jan;44(1):104-10.
78. Ayuk F, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Sayer HG, Zabelina T, Zander AR, Kroger N. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia. 2004 Mar;18(3):659-62.
79. Kroger N, Damon L, Zander AR, Wandt H, Derigs G, Ferrante P, Demirer T, Rosti G; Solid Tumor Working Party of the European Group for Blood and Marrow Transplantation; German Adjuvant Breast Cancer Study Group; University of California, San Francisco. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. Bone Marrow Transplant. 2003 Dec;32(12):1153-7.
80. Ayuk F, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Sayer HG, Zabelina T, Zander AR, Kröger N. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2003, 1-3
81. Zander AR, Kröger N, Schmoor C, Krüger W, Möbus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Wandz H, Possinger K, Trümper L, Pflüger K-H, Kreienberg R, Carstensen M, Franke A, Schmidt EH, Jänicke F, Hossfeld DK, Schumacher M, Jonat W on behalf of the German Breast Cancer Study Group (GABG), Hamburg, Germany. High-Dose Chemotherapy with Autologous Haematopoietic Stem-Cell Support (HSCS) vs. Standard-Dose Chemotherapy in Breast Cancer Patients with 10 or More Positive Lymphnodes: First Results of a Randomised Trial. Journal of Clinical Oncology. 2004 Jun 15;22(12):2273-83. Epub 2004 Apr 26.
82. Koustikova O, Wahlers A, Kühlcke K, Stähle B, Zander AR, Baum C, Fehse B: Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 2003; 102: 3934-3937
83. Kröger N, Damon L, Zander AR, Wandt H, Derigs G, Ferranze P, Demirer T, Rosti G: Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. Bone Marrow Transplantation (2003) 32; 1153-1157
84. Zander AR, Kröger N, Schleuning M, Finke J, Zabelina T, Beelen D, Schwerdtfeger R, Baurmann H, Bornhäuser M, Ehninger G, Fauser AA, Kiehl M, Trenschel R, Ottinger HD, Bertz H, Berger J, Kolb H-J, Schaefer UW: Chronic Myeloid Leukaemia. ATG as part of the conditioning regimen reduces transplant-related mortality [TRM] and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia [CML]. Bone Marrow Transplantation (2003) 32, 355-361
85. Einsele H, Bamberg M, Budach W, Schmidberger H, Hess CF, Wörmann B, Meisner C, Straka C, Hebart H, Trümper L, Köger N, Zander AR, Hegewisch-Becker S, Hossfeld DK, Schmidt H, Müller P, Schlimok G, Hertenstein B, Peest D, Metzner B, Frickhofen N, Kanz L, Bensinger WI. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplantation (2003) 32, 593-599
86. Zander AR, Stute N, Fehse B, Lange C. Adulte oder emryonale Stammzellen? In: Albrecht, ST et al. (Hrsg), Stammzellforschung. Debatte zwischen Ethik, Politik und Geschäft. Hamburg 2003. S. 9-23
87. Weber M, Kröger N, Langer F, Hansen A, Zabelina T, Eifrig B, Hossfeld DK, Zander AR. Non-overt disseminated intravascular coagulationin patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cel transplantation. Bone Marrow Transplantation (2003) 31, 817-822
88. Kustikova OS, Wahlers A, Kühlcke K, Stähle B, Zander AR, Baum C, Fehse B. (2003) Dose finding with retroviral vectors: Correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 102:3934-3937.
89. Fiegel HC, Kluth J, Lioznov MV, Holzhüter S, Fehse B, Zander AR, Kluth D. Hepatic lineages isolated from developing rat liver show different ways of maturation. Biochemical and Biophysical Research Communications (2003) 305, 46-53
90. Kröger N, Zander AR, Martinelli G, Ferrante P, Moraleda JM, Da Prada GA, Demirer T, Socie G, Rosti G. Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation. Annals of Oncology 14 (2003), 554-558
91. Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schäfer-Eckart K, Wittkowsky G, Schmitz N, Krüger W, Zabelina T, Renges H, Ayuk F, Krüll A, Zander AR. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM). Bone Marrow Transplantation (2003) 31, 973-979
92. Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol (2003) 82: 336-342
93. Fehse N, Fehse B, Kröger N, Zabelina T, Freiberger P, Krüger W, Kabisch H, Erttmann R, Zander AR. Influence of Anti-Thymocyte Globulin As Part of the Conditioning Regimen on Immune Reconstitution Following Matched Related Bone Marrow Transplantation. Journal of Hematotherapy & Stem Cell Research (2003) 12: 237-242
94. Fiegel HC, Lioznov MV, Cortes-Dericks L, Lange C, Kluth D, Fehse B, Zander AR. Liver-Specific Gene Expression in Cultured Human Hemtopoietic Stem Cells. Stem Cells (2003); 21: 98-104
95. Krüger WH, Lange A, Badbaran A, Gutensohn K, Kröger N, Zander AR. Detection of disseminated epithelial cancer cells by liquid culture – factors interfering with the standardization of assays. Cytotherapy (2003) Vol. 5, No.3, 252-258
96. Shimoni A, Kröger N, Zander AR, Rowe JM, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003 Feb;17(2):290-297
97. Fiegel HC, Park JJ, Lioznov MV, Martin A, Jaeschke-Melli S, Kaufmann PM, Fehse B, Zander AR, Kluth D. Characterization of cell types during rat liver development. Hepatology 2003 Jan;37(1):148-154
98. Kröger N, Zander AR, Martinelli G, Ferrante P, Moraleda JM, Da Prada GA, Demirer T, Socie G, Rosti G. Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation. 2003 Annals of Ontology 14: 554-558
99. Schetelig J, Thiede C, Bornhäuser M, Schwerdtfeger R, Kiehl M, Beyer J, Kröger N, Hensel M, Scheffold C, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W. Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia. Ann Hematol 2002;81 Suppl 2:S47-8
100. Stute N, Fehse B, Schröder J, Arps S, Adamietz P, Held KR, Zander AR. Human mesenchymal stem cells are not of donor origin in patients with severe aplastic anemia who underwent sex-mismatched allogeneic bone marrow transplant. J Hematother Stem Cell Res 2002 Dec;11(6):977-984
101. Tögel F, Kröger N, Korioth F, Fehse B, Zander AR. Molecular Methods for Detection and Quantification of Myeloma Cells after Bone Marrow Transplantation: Comparison between Real-Time Quantitative and Nested PCR. J Hematother Stem Cell Res 2002 Dec;11(6):971-976
102. Kröger N, Zabelina T, Renges H, Kruger W, Kordes U, Rischewski J, Schrum J, Horstmann M, Ayuk F, Erttmann R, Kabisch H, Zander AR. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin. Ann Hematol 2002 Nov;81(11):627-631
103. Hessling J, Kröger N, Werner M, Zabelina T, Hansen A, Kordes U, Ayuk FA, Renges H, Panse J, Erttmann R, Zander AR. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002 Dec;119(3):769-772
104. Fehse B, Kustikova OS, Li Z, Wahlers A, Bohn W, Beyer WR, Chalmers D, Tiberghien P, Kühlcke K, Zander AR, Baum C. A novel 'sort-suicide' fusion gene vector for T cell manipulation. Gene Ther 2002 Dec;9(23):1633-1638
105. Kröger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, Zabelina T, Fehse B, Ayuk F, Wittkowsky G, Schmitz N, Zander AR. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 100, 2002 Dec 1;100(12):3919-3924
106. Kröger N, Zander AR. Dose and schedule effect of G-GSF for stem cell mobilization in healthy donors for allogeneic transplantation. Leuk Lymphoma 2002 Jul;43(7):1391-1394
107. Hauber HP, Mikkila A, Erich JM, Kroger N, Meyer A, Schoder V, Zander AR, Pforte A. TNFalpha, interleukin-10 and interleukin-18 expression in cells of the bronchoalveolar lavage in patients with pulmonary complications following bone marrow or peripheral stem cell transplantation: a preliminary study. Bone Marrow Transplant 2002 Oct;30(8):485-490
108. Pick M, Eldor A, Grisaru D, Zander AR, Shenhav M, Deutsch VR. Ex vivo expansion of megakaryocyte progenitors from cryopreserved umbilical cord blood. A potential source of megakaryocytes for transplantation. Exp Hematol 2002 Sep;30(9):1079-1087
109. Li Z, Fehse B, Schiedlmeier B, Düllmann J, Frank O, Zander AR, Ostertag W, Baum C. Persisting multilineage transgene expression in the clonal progeny of a hematopoietic stem cell. Leukemia 2002 Sep;16(9):1655-1663
110. Kröger N, Zabelina T, Kruger W, Renges H, Stute N, Rischewski J, Sonnenberg S, Ayuk F, Tögel F, Schade U, Fiegel H, Erttmann R, Löliger C, Zander AR. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002 Apr;29(8):683-689
111. Graf Finckenstein F, Zabelina T, Durken M, Dahlke J, Kroger N, Kruger W, Janka-Schaub G, Erttmann R, Zander AR, Kabisch H. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG] [Article in German] Klin Padiatr 2002 Jul-Aug;214(4):206-211
112. Kröger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, Fehse B, Tögel F, Wittkowsky G, Kuse R, Zander AR. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100, 2002 Aug 1;100(3):755-760
113. Ayuk FA, Zander AR, Fehse B. T lymphocytes as targets of gene transfer with Moloney-type retroviral vectors. Curr Gene Ther 2001 Nov;1(4):325-337
114. Begemann PGC, Hassan HT, Kröger N, Krüger W, Kabisch H, Zander AR. Correlation of time to platelet engraftment with amount of transplanted CD34+CD41+ cells after allogeneic bone marrow transplantation. Journal of Hematotherapy & Stem Cell Research 2002; 11: 321-326
115. Kröger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Biezen A, Niederwieser D, Zander AR, De Witte T. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002 Jul;118(1):67-73
116. Kröger N, Renges H, Sonnenberg S, Krüger W, Gutensohn K, Dielschneider T, Cortes-Dericks L, Zander AR. Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant 2002 May;29(9):727-730
117. Kottaridis PD, Peggs K, Schmitz N, Dreger P, Boogaerts MA, Ferrant A, Demuynck HM, Zander A, Link H, Matcham J, Linch DC, Borkett K, Goldstone AH. Survival and freedom from progression in autotransplant lymphoma patients is independent of stem cell source: further follow-up from the original randomised study to assess engraftment. Leuk Lymphoma 2002 Mar;43(3):531-536
118. Begemann PG, Hassan HT, Kröger N, Krüger W, Kabisch H, Zander AR. Correlation of time to platelet engraftment with amount of transplanted CD34+CD41+ cells after allogeneic bone marrow transplantation. J Hematother Stem Cell Res 2002 Apr;11(2):321-326
119. Kühlcke K, Fehse B, Schilz A, Loges S, Lindemann C, Ayuk F, Lehmann F, Stute N, Fauser AA, Zander AR, Eckert HG. Highly efficient retroviral gene transfer based on centrifu-gation-mediated vector preloading of tissue culture vessels. Mol Ther 2002 Apr;5(4):473-478
120. Carpinteiro A, Peinert S, Ostertag W, Zander AR, Hossfeld DK, Kühlcke K, Eckert HG, Baum C, Hegewisch-Becker S. Genetic protection of repopulating hematopoietic cells with an improved MDR1-retrovirus allows administration of intensified chemotherapy following stem cell transplantation in mice. Int J Cancer 2002 Apr 10;98(5):785-792
121. Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 2002 Feb;81(2):96-102
122. Eiermann TH, Sahm H, Freitag C, Zander AR. The effect of IgM-enriched human Ig and rabbit antithymocyte globulin on the stimulation of mononuclear cells. Scand J Immunol 2001 Dec;54(6):626-629
123. Schulz-Kindermann F, Hennings U, Ramm G, Zander AR, Hasenbring M. The role of biomedical and psychosocial factors for the prediction of pain and distress in patients undergoing high-dose therapy and BMT/PBSCT. Bone Marrow Transplant 2002 Feb;29(4):341-351
124. Schetelig J, Kröger N, Held TK, Thiede C, Krusch A, Zabelina T, Dubiel M, Rick O, Bornhäuser M, Ehninger G, Zander AR, Siegert W. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica 2002 Mar;87(3):299-305
125. Krüger WH, Hornung RJ, Hertenstein B, Kern WV, Kröger N, Ljungman P, Zander AR. European group for blood and marrow transplantation. Practices of infectious disease prevention and management during hematopoietic stem cell transplantation: a survey from the European group for blood and marrow transplantation. J Hematother Stem Cell Res 2001 Dec;10(6):895-903
126. Ottinger HD, Muller CR, Goldmann SF, Albert E, Arnold R, Beelen DW, Blasczyk R, Bunjes D, Casper J, Ebell W, Ehninger G, Eiermann T, Einsele H, Fauser A, Ferencik S, Finke J, Hertenstein B, Heyll A, Klingebiel T, Knipper A, Kremens B, Kolb HJ, Kolbe K, Lenartz E, Lindemann M, Muller CA, Mytilineos J, Niederwieser D, Runde V, Sayer H, Schaefer UW, Schmitz N, Schroder S, Schulze-Rath R, Schwerdtfeger R, Siegert W, Thiele B, Zander AR, Grosse-Wilde H. Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells. Ann Hematol 2001 Dec;80(12):706-714
127. Krüger WH, Jung R, Detlefsen B, Mumme S, Badbaran A, Brandner J, Renges H, Kroger N, Zander AR. Interference of cytokeratin-20 and mammaglobin-reverse-transcriptase polymerase chain assays designed for the detection of disseminated cancer cells. Med Oncol 2001;18(1):33-38
128. Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 2001 Oct;28(7):643-647
129. Krüger WH, Kröger N, Tögel F, Renges H, Badbaran A, Hornung R, Jung R, Gutensohn K, Gieseking F, Jänicke F, Zander AR. Disseminated breast cancer cells prior to and after high-dose therapy. J Hematother Stem Cell Res 2001 Oct;10(5):681-689
130. Zander AR, Kroger N. [High-dosage treatment of breast cancer--in favour] [Article in German] Dtsch Med Wochenschr 2001 Sep 28;126(39):1091
131. Fehse B, Chukhlovin A, Kühlcke K, Marinetz O, Vorwig O, Renges H, Krüger W, Zabelina T, Dudina O, Finckenstein FG, Kröger N, Kabisch H, Hochhaus A, Zander AR. Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. J Hematother Stem Cell Res 2001 Jun;10(3):419-425
132. Eiermann TH, Freitag S, Cortes-Dericks L, Sahm H, Zander AR. Jurkat cell-reactive anti-thymocyte globulin assessed ex vivo by flow cytometry persists three weeks in circulation. J Hematother Stem Cell Res 2001 Jun;10(3):385-390
133. Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Schaf-hausen P, Jaburg N, Löliger C, Schafer P, Hinke A, Zander AR. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 2001 Jun;113(4):1060-1071
134. Hanel M, Kröger N, Kroschinsky F, Birkmann J, Hanel A, Herbst R, Naumann R, Friedrichsen K, Ehninger G, Zander AR, Fiedler F. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma. J Cancer Res Clin Oncol 2001;127(6):387-395
135. Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Dürken M, Graf von Finkenstein F, Erttmann R, Kabisch H, Schafhausen P, Jaburg N, Löliger C, Zander AR. Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Hematol 2001 Apr;80(4):209-215
136. Krüger W, Kröger N, Tögel F, Badbaran A, Renges H, Gieseking F, Gutensohn K, Jänicke F, Zander AR. Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells. J Hematother Stem Cell Res 2001 Apr;10(2):303-307
137. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C, Remberger M, Michel G, Arcese W, Dallorso S, Tiedemann K, Busca A, Chan KW, Kato S, Ortega J, Vowels M, Zander A, Souillet G, Oakill A, Woolfrey A, Pay AL, Green A, Garnier F, Ionescu I, Wernet P, Sirchia G, Rubinstein P, Chevret S, Gluckman E. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001 May 15;97(10):2962-2971
138. Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H, Jaburg N, Löliger C, Krull A, Zander AR. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant 2001 Feb;27(4):349-354
139. Tögel F, Datta C, Badbaran A, Kröger N, Renges H, Gieseking F, Jünicke F, Zander AR, Krüger W. Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells. J Hematother Stem Cell Res 2001 Feb;10(1):141-145
140. Kröger N, Krüger W, Renges H, Zabelina T, Stute N, Jung R, Wittkowsky G, Kuse R, Zander A. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001 Feb;112(2):421-423
141. Krüger W, Datta C, Badbaran A, Tögel F, Gutensohn K, Carrero I, Kröger N, Janicke F, Zander AR. Immunomagnetic tumor cell selection--implications for the detection of disseminated cancer cells. Transfusion 2000 Dec;40(12):1489-1493
142. Kröger N, Renges H, Krüger W, Gutensohn K, Löliger C, Carrero I, Cortes L, Zander AR. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000 Dec;111(3):761-765
143. Kröger N, Hoffknecht M, Krüger W, Zeller W, Renges H, Stute N, Zschaber R, Zander AR. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Ann Hematol 2000 Oct;79(10):578-580
144. Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplant 2000 Oct;26(7):711-716
145. Krüger W, Kröger N, Zander AR. MUC1 expression in hemopoietic tissues. J Hematother Stem Cell Res 2000 Aug;9(4):409-410
146. Krüger W, Lohner R, Jung R, Kröger N, Zander AR. Expression of human milk fat globulin proteins in cells of haemopoietic origin. Br J Cancer 2000 Oct;83(7):874-879
147. Damon LE, Wolf JL, Rugo HS, Gold E, Zander AR. Cassidy M, Cecchi G, Cohen N, Irwin D, Tracy M, Ries CA, Linker CA. High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant 2000 Aug;26(3):257-268
148. Fehse B, Richters A, Putimtseva-Scharf K, Klump H, Li Z, Ostertag W, Zander AR, Baum C. CD34 splice variant: an attractive marker for selection of gene-modified cells. Mol Ther 2000 May;1(5 Pt 1):448-456
149. Kühlcke K, Ayuk FA, Li Z, Lindemann C, Schilz A, Schade UM, Fauser AA, Zander AR, Eckert HG, Fehse B. Retroviral transduction of T lymphocytes for suicide gene therapy in allogeneic stem cell transplantation. Bone Marrow Transplant 2000 May;25 Suppl 2:S96-98
150. Fehse B, Goldmann M, Frerk O, Bulduk M, Zander AR. Depletion of alloreactive donor T cells using immunomagnetic cell selection. Bone Marrow Transplant 2000 May;25 Suppl 2:S39-242
151. Hänel M, Kröger N, Hoffknecht MM, Peters SO, Metzner B, Fiedler F, Braumann D, Schubert JC, Illiger HJ, Hanel A, Krüger WH, Zeller W, Weh HJ, Hossfeld DK, Zander AR. ASHAP--an effective salvage therapy for recurrent and refractory malignant lymphomas. Ann Hematol 2000 Jun;79(6):304-311
152. Fehse B, Frerk O, Goldmann M, Bulduk M, Zander AR. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br J Haematol 2000 Jun;109(3):644-651
153. Simonsson B, Totterman T, Hokland P, Lauria F, Carella AM, Fernandez MN, Rozman C, Ferrant A, de Witte T, Zander AR, Meier K, Hansson F, Nilsson BI. Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation. Bone Marrow Transplant 2000 Jun;25(11):1121-1127
154. Dürken M, Herrnring C, Finckh B, Nagel S, Nielsen P, Fischer R, Berger HM, Moison RM, Pichlmeier U, Kohlschütter B, Zander AR, Kohlschütter A. Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. Free Radic Biol Med 2000 Mar 15;28(6):887-894
155. Zeller W, Kröger N, Berger J, Krueger W, Dierlamm J, Stockschläder M, Gutensohn K, Hossfeld DK, Zander AR. Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells. J Hematother Stem Cell Res 1999 Oct;8(5):539-546
156. Clausen J, Stockschläder M, Fehse N, Hassan HT, Gabl C, Zander AR. Blood-derived macrophage layers in the presence of hydrocortisone support myeloid progenitors in long-term cultures of CD34+ cord blood and bone marrow cells. Ann Hematol 2000 Feb;79(2):59-65
157. Kröger N, Krüger W, Renges H, Zeller W, Rauhoft C, Löliger C, Zander AR. Comparison of progenitor cell collection on day 4 or day 5 after steady-state stimulation with G-CSF alone in breast cancer patients: influence on CD34+ cell yield, subpopulation, and breast cancer cell contamination. J Hematother Stem Cell Res 2000 Feb;9(1):111-117
158. Steffen M, Pichlmeier U, von dem Busche C, Zander AR. Serum levels of stem cell factor in patients during transplantation of bone marrow or peripheral blood stem cells. J Hematother Stem Cell Res 2000 Feb;9(1):55-61
159. Krüger W, Jung R, Kröger N, Gutensohn K, Fiedler W, Neumaier M, Jänicke F, Wagener C, Zander AR. Sensitivity of assays designed for the detection of disseminated epithelial tumor cells is influenced by cell separation methods. Clin Chem 2000 Mar;46(3):435-436
160. Kröger N, Rauhoft C, Zeller W, Renges H, Hassan HT, Krüger W, Schuch G, Wacker-Backhaus G, Colberg H, Kuse R, Gutensohn K, Löliger C, Zander AR. Efficacy of further attempts to mobilize CD34+ peripheral stem cells with alternative procedures after primary failure. Acta Haematol 2000;102(3):144-147
161. Weber C, Maas R, Steiner P, Kramer J, Bumann D, Zander AR, Bucheler E. [Importance of digital thoracic radiography in the diagnosis of pulmonary infiltrates in patients with bone marrow transplantation during aplasia] [Article in German] Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1999 Oct;171(4):294-301
162. Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H, Siegert W, Finke J, Ehninger G, Holler E, Berger U, Pfirrmann M, Muth A, Zander AR, Fauser AA, Heyll A, Nerl C, Hossfeld DK, Loffler H, Pralle H, Queisser W, Tobler A. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999 Dec 1;94(11):3668-3677
163. Jung R, Petersen K, Kruger W, Wolf M, Wagener C, Zander A, Neumaier M. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br J Cancer 1999 Nov;81(5):870-873
164. Kröger N, Achterrath W, Hegewisch-Becker S, Mross K, Zander AR. Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev 1999 Oct;25(5):279-291
165. Dürken M, Horstmann M, Bieling P, Erttmann R, Kabisch H, Löliger C, Schneider EM, Hellwege HH, Krüger W, Kröger N, Zander AR, Janka GE. Improved outcome in haemophago-cytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients. Br J Haematol 1999 Sep;106(4):1052-1058
166. Ayuk F, Li Z, Kühlcke K, Lindemann C, Schade U, Eckert HG, Zander A, Fehse B. Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements. Gene Ther 1999 Oct;6(10):1788-1792
167. Hildinger M, Schilz A, Eckert HG, Bohn W, Fehse B, Zander A, Ostertag W, Baum C. Bicistronic retroviral vectors for combining myeloprotection with cell-surface marking. Gene Ther 1999 Jul;6(7):1222-1230
168. Skiera D, Zeller W, Zander AR. Graft engineering of G-CSF-mobilized allogeneic leukapheresis products by counterflow centrifugal elutriation after CD34 column adsorption. J Hematother 1999 Jun;8(3):299-304
169. Krüger W, Tögel F, Kröger N, Rössing S, Gieseking F, Gutensohn K, Lindner C, Jänicke F, Zander AR. Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer. Med Oncol 1999 Apr;16(1):17-22
170. Zander AR, Zabelina T, Kröger N, Renges H, Krüger W, Löliger C, Dürken M, Stockschläder M, de Wit M, Wacker-Backhaus G, Bielack S, Jaburg N, Rüssmann B, Erttmann R, Kabisch H. Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant 1999 May;23(9):889-893
171. Kapaun P, Dittmann RW, Granitzny B, Eickhoff W, Wulbrand H, Neumaier-Probst E, Zander A, Kohlschuetter A. Slow progression of juvenile metachromatic leukodystrophy 6 years after bone marrow transplantation. J Child Neurol 1999 Apr;14(4):222-228
172. Eiermann TH, Lambrecht P, Zander AR. Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant 1999 Apr;23(8):779-781
173. Todriia TV, Drize NI, Chertkov IL, Grimm I, Zander A. [Telomerase activity in the mouse bone marrow and subpopulations of spleen colony-forming units] [Article in Russian] Biull Eksp Biol Med 1999 Mar;127(3):311-313
174. Krüger W, Rüssmann B, Kröger N, Salomon C, Ekopf N, Elsner HA, Kaulfers PM, Mack D, Fuchs N, Dürken M, Kabisch H, Erttmann R, Zander AR. Early infections in patients undergoing bone marrow or blood stem cell transplantation--a 7 year single centre investigation of 409 cases. Bone Marrow Transplant 1999 Mar;23(6):589-597
175. Kröger N, Zeller W, Hassan HT, Krüger W, Gutensohn K, Löliger C, Zander AR. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg). Bone Marrow Transplant 1999 Jan;23(2):125-129
176. Hassan HT, Hinz T, Kroger N, Zeller W, Zander AR. Factors influencing platelet recovery after autologous transplantation of G-CSF-mobilized peripheral blood stem/progenitor cells following myeloablative therapy in 50 heavily pretreated lymphoma patients. Clin Lab Haematol 1999 Feb;21(1):21-27
177. Zander AR, Berger C, Kröger N, Stockshläder M, Krüger W, Horstmann M, Grimm J, Zeller W, Kabisch H, Erttmann R, Schonrock P, Kuse R, Braumann D, Illiger HJ, Fiedler W, de Witt M, Hossfeld KD, Weh HJ. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin Cancer Res 1997 Dec;3(12 Pt 2):2671-2675
178. Li ZX, Schade UM, Fehse B, Stockschlader M, Uhde A, Koch S, Goller B, Ruger R, Fehse N, Zander AR. High-efficiency retroviral vector-mediated gene transfer into human T lymphocytes. Adv Exp Med Biol 1998;451:375-378
179. Krüger WH, Kröger N, Rüssmann B, Renges H, Kabisch H, Zander AR. Treatment of mycotic infections after haemopoietic progenitor cell transplantation with liposomal amphotericin-B. Bone Marrow Transplant 1998 Dec;22 Suppl 4:S10-13
180. Kröger N, Krüger W, Wacker-Backhaus G, Hegewisch-Becker S, Stockschläder M, Fuchs N, Russmann B, Renges H, Durken M, Bielack S, de Wit M, Schuch G, Bartels H, Braumann D, Kuse R, Kabisch H, Erttmann R, Zander AR. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1998 Dec;22(11):1029-1033
181. Jung R, Krüger W, Hosch S, Holweg M, Kröger N, Gutensohn K, Wagener C, Neumaier M, Zander AR. Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. Br J Cancer 1998 Nov;78(9):1194-1198
182. Schulz-Kindermann F, Weis J, Ramm G, Linhart D, Birmele M, Zander AR, Hasenbring M. [Psychological problems and treatment possibilities in intensive care medicine exemplified by bone marrow transplantation] [Article in German] Psychother Psychosom Med Psychol 1998 Sep-Oct;48(9-10):390-397
183. Dürken M, Schneider EM, Blutters-Sawatzki R, Stollmann-Gibbels B, Nessler G, Bretz R, Korholz D, Probst EN, Holsten-Griffin H, Harps E, Zander AR, Janka GE. [Treatment of hemophagocytic lymphohistiocytosis, HLH, with bone marrow transplantation] [Article in German]Klin Padiatr 1998 Jul-Aug;210(4):180-184
184. Kröger N, Zeller W, Fehse N, Hassan HT, Krüger W, Gutensohn K, Lölliger C, Zander AR. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients. Br J Haematol 1998 Sep;102(4):1101-1106
185. Fehse B, Schade UM, Li Z, Uhde A, Koch S, Goller B, Rüger R, Fehse N, Stockschläder M, Zander AR. Highly-efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectin. Br J Haematol 1998 Jul;102(2):566-574
186. Kröger N, Zeller W, Hassan HT, Krüger W, Renges H, Hummel K, Gutensohn K, Lölliger C, Zander AR. Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Ann Hematol 1998 Jun;76(6):257-262
187. Kröger N, Hoffknecht M, Hanel M, Krüger W, Zeller W, Stockschläder M, de Wit M, Weh HJ, Kabisch H, Erttmann R, Zander AR. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Bone Marrow Transplant 1998 Jun;21(12):1171-1175
188. Burmeister MA, Standl T, Brauer P, Ramsperger K, Kroger N, Zander A, Schulte am Esch J. Safety and efficacy of spinal vs general anaesthesia in bone marrow harvesting. Bone Marrow Transplant 1998 Jun;21(11):1145-1148
189. Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, Bourquelot P, Greinix H, Frickhofen N, Ringden O, Zander A, Apperley JF, Gorin C, Borkett K, Schwab G, Goebel M, Russell NH, Gratwohl A. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998 May;21(10):995-1003
190. Fehse B, Li Z, Schade UM, Uhde A, Zander AR. Impact of a new generation of gene transfer markers on gene therapy. Gene Ther 1998 Apr;5(4):429-430
191. Krüger W, Gruber M, Hennings S, Fehse N, Fehse B, Gutensohn K, Kröger N, Zander AR. Purging and haemopoietic progenitor cell selection by CD34+ cell separation. Bone Marrow Transplant 1998 Apr;21(7):665-671
192. Kröger N, Zeller W, Hassan HT, Krüger W, Löliger C, Zander AR. Schedule-depen-dency of granulocyte colony-stimulating factor in peripheral blood progenitor cell mobilization in breast cancer patients. Blood 1998 Mar 1;91(5):1828
193. Kröger N, Hoffknecht M, Dreger P, Krüger W, Zeller W, Krull A, Stockschläder M, Bittner S, Weh HJ, Zander AR. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 1998 Jan;21(1):55-57
194. Grimm J, Zeller W, Zander AR. Soluble interleukin-2 receptor serum levels after alloge-neic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant 1998 Jan;21(1):29-32
195. Dittmer R, Benn HP, Cassens U, Schwarz K, Löliger C, Zander AR, Kühnl P. [Measurement of alloreactive anti-recipient helper T-cell precursors after allogenic bone marrow transplantation] [Article in German] Beitr Infusionsther Transfusionsmed 1994;32:272-275
196. Kröger N, Zeller W, Hassan HT, Dierlamm J, Zander AR. Difference between expression of adhesion molecules on CD34+ cells from bone marrow and G-CSF-stimulated peripheral blood. Stem Cells 1998;16(1):49-53
197. Gutensohn K, Zander AR, Rowley SD, Hester J, Kuehnl P. Protein A immunoadsorption in alloimmunized patients refractory to platelet transfusions and in patients with treatment-resistant immune thrombocytopoenic purpura. Transfus Sci 1998 Mar;19 Suppl:47-52
198. Steffen M, Pichlmeier U, Zander A. Inverse correlation of interleukin-6 with soluble interleukin-6 receptor after transplantation of bone marrow or peripheral blood stem cells. Bone Marrow Transplant 1997 Nov;20(9):715-20
199. Fehse B, Uhde A, Fehse N, Eckert HG, Clausen J, Rüger R, Koch S, Ostertag W, Zander AR, Stockschlader M. Selective immunoaffinity-based enrichment of CD34+ cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (deltaLNGFR) gene. Hum Gene Ther 1997 Oct 10;8(15):1815-24
200. Link H, Kolb HJ, Ebell W, Hossfeld DK, Zander A, Niethammer D, Wandt H, Grosse-Wilde H, Schaefer UW. [Transplantation of hematopoietic stem cells. II: Indications for transplantation of hematopoietic stem cells after myeloablative therapy] [Article in German] Med Klin 1997 Sep 15;92(9):534-45
201. Link H, Kolb HJ, Ebell W, Hossfeld DK, Zander A, Niethammer D, Wandt H, Grosse-Wilde H, Schaefer UW. [Transplantation of hematopoietic stem cells. I: Definitions, principle indications, complications] [Article in German] Med Klin 1997 Aug 15;92(8):480-91, 505
202. Hassan HT, Krog C, Stockschläder M, Zeller W, Krüger W, Erttmann R, Zander AR. Factors influencing haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis. A single-centre experience. Support Care Cancer 1997 Jul;5(4):299-306
203. Stockschläder M, Hassan HT, Zeller W, Krüger W, Clausen J, Löliger C, Dieck AT, Kröger N, Link H, Kabisch H, Hossfeld DK, Zander A. Allogeneic transplantation with CD34+-selected cells. Leuk Lymphoma 1997 Mar;25(1-2):145-51
204. Drize N, Chertkov J, Sadovnikova E, Tiessen S, Zander A. Long-term maintenance of hematopoiesis in irradiated mice by retrovirally transduced peripheral blood stem cells. Blood 1997 Mar 1;89(5):1811-7
205. Krüger W, Stockschläder M, Sobottka I, Betker R, De Wit M, Kröger N, Grimm J, Arland M, Fiedler W, Erttmann R, Zander AR. Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation. Leuk Lymphoma 1997 Feb;24(5-6):491-9
206. Stockschläder M, Hassan HT, Krog C, Krüger W, Löliger C, Horstman M, Altnöder M, Clausen J, Grimm J, Kabisch H, Zander A. Long-term follow-up of leukaemia patients after related cryopreserved allogeneic bone marrow transplantation. Br J Haematol 1997 Feb;
207. 96(2):382-6
208. Koehne G, Zeller W, Stockschlaeder M, Zander AR. Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997 Jan;19(2):149-56
209. Hassan HT, Sadovinkova EYu, Drize NJ, Zander AR, Neth R. Fibronectin increases both non-adherent cells and CFU-GM while collagen increases adherent cells in human normal long-term bone marrow cultures. Haematologia (Budap) 1997;28(2):77-84
210. Dürken M, Nielsen P, Knobel S, Finckh B, Herrnring C, Dresow B, Kohlschütter B, Stockschläder M, Krüger WH, Kohlschütter A, Zander AR. Nontransferrin-bound iron in serum of patients receiving bone marrow transplants. Free Radic Biol Med 1997;22(7):1159-63
211. Hassan HT, Krog C, Stockschläder M, Schleimer B, Zeller W, Krüger W, Erttmann R, Zander AR. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience. Anticancer Res 1997 Jan-Feb;17(1B):589-99
212. Meier-Tackmann D, Agarwal DP, Krueger W, Dereskewitz C, Hassan HT, Zander AR. Changes in aldehyde dehydrogenase isozymes expression in long-term cultures of human hematopoietic progenitor cells. Adv Exp Med Biol 1997;414:47-57
213. Smith TJ, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder MH. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997 Jan;15(1):5-10
214. Stockschläder M, Fiedler W, Zander A, Weh HJ, Hossfeld DK. Philadelphia chromosome-positive secondary acute myeloid leukemia following high-dose chemotherapy with peripheral blood progenitor cell support for relapsed low-grade non-Hodgkin's lymphoma. Ann Hematol 1996 Dec;73(6):291-3
215. Hassan HT, Stockschläder M, Schleimer B, Krüger W, Zander AR. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors. Transpl Immunol 1996 Dec;4(4):319-23
216. Stockschläder M, Hassan HT, Krüger W, Kabisch H, Zander A. Comparison of haematological recovery kinetics after myeloablative therapy between sibling allogeneic bone marrow and peripheral blood progenitor cell transplantation in the same adult acute lymphoblastic leukaemia patient. Leuk Res 1996 Nov-Dec;20(11-12):993-6
217. Euler HH, Marmont AM, Bacigalupo A, Fastenrath S, Dreger P, Hoffknecht M, Zander AR, Schalke B, Hahn U, Haas R, Schmitz N. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996 Nov 1;88(9):3621-5
218. Eckert HG, Stockschläder M, Just U, Hegewisch-Becker S, Grez M, Uhde A, Zander A, Ostertag W, Baum C. High-dose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral vectors. Blood 1996 Nov 1;88(9):3407-15
219. Zander AR, Krüger W, Kröger N, Damon L, Konigmann M, Berdel WE, Gieseking F, Schafer-Eckart K, Mobus V, Frickhofen N, Wandt H, Illiger HJ, Metzner B, Kolbe K, Wormann B, Trumper L, Huber C, Hossfeld DK, Maass H, Jonat W. High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study. Bone Marrow Transplant 1996 Sep;18 Suppl 1:S24-5
220. Krüger WH, Stockschläder M, Hennings S, Aschenbrenner M, Gruber M, Gutensohn K, Löliger C, Gieseking F, Jonat W, Zander AR. Detection of cancer cells in peripheral blood stem cells of women with breast cancer by RT-PCR and cell culture. Bone Marrow Transplant 1996 Sep;18 Suppl 1:S18-20
221. Hassan HT, Zander AR. Thrombocytopenia after high-dose chemotherapy and autologous stem cell transplantation: an unresolved problem and possible approaches to resolve it. J Hematother 1996 Aug;5(4):407-14
222. Steffen M, Dürken M, Pichlmeier U, von dem Busche C, Stockschläder M, Krüger W, Budde-Steffen C, Zander A. Serum interleukin-6 levels during bone marrow transplantation: impact on transplant-related toxicity and engraftment. Bone Marrow Transplant 1996 Aug;18(2):301-7
223. Hassan HT, Zeller W, Stockschläder M, Krüger W, Hoffknecht MM, Zander AR. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection. Stem Cells 1996 Jul;14(4):419-29
224. Drize N, Chertkov J, Samoilina N, Zander A. Effect of cytokine treatment (granulocyte colony-stimulating factor and stem cell factor) on hematopoiesis and the circulating pool of hematopoietic stem cells in mice. Exp Hematol 1996 Jun;24(7):816-22
225. Zeller W, Gutensohn K, Stockschläder M, Dierlamm J, Kröger N, Koehne G, Hummel K, Kabisch H, Weh HJ, Kühnl P, Hossfeld DK, Zander AR. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. Bone Marrow Transplant 1996 May;17(5):709-13
226. Hassan HT, Biermann B, Zander AR. Maintenance and expansion of erythropoiesis in human long-term bone marrow cultures in presence of erythropoietin plus stem cell factor and interleukin-3 or interleukin-11. Eur Cytokine Netw 1996 Apr-Jun;7(2):129-36
227. Hassan HT, Stockschläder M, Krüger W, Hoffknecht H, Zander AR. G-CSF administration following peripheral blood selected CD34-positive cells autologous transplantation accelerates haematological recovery after myeloablative therapy. Br J Haematol 1996 Mar;92(4):1027-9
228. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HM, Link H, Zander A, Barge A. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996 Feb 10;347(8998):353-7
229. Stockschläder M, Krüger W, tom Dieck A, Horstmann M, Altnöder M, Löliger C, Fiedler W, Hoffknecht M, Erttmann R, Zander A. Use of cryopreserved bone marrow in unrelated allogeneic transplantation. Bone Marrow Transplant 1996 Feb;17(2):197-9
230. Mross K, Reifke J, Bewermeier P, Krüger W, Hossfeld DK, Zander A. The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. Ann Oncol 1996 Jan;7(1):83-8
231. Stockschläder M, Hassan HT, Löliger C, Zander AR. Long-term remission of chronic myelogenous leukaemia following allogeneic transplantation of peripheral blood progenitor cells in the fourth chronic phase after failing previous bone marrow transplantation and donor leukocyte transfusion. Acta Haematol 1996;96(4):262-3
232. Krüger W, Krzizanowski C, Holweg M, Stockschläder M, Kröger N, Jung R, Mross K, Jonat W, Zander AR. Reverse transcriptase/polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients. J Cancer Res Clin Oncol 1996;122(11):679-86
233. Krüger W, Sobottka I, Stockschläder M, Mross K, Hoffknecht M, Rüssmann B, Horstmann M, Betker R, Zander A. Fatal outcome of disseminated candidosis after allogeneic bone marrow transplantation under treatment with liposomal and conventional amphotericin-B. A report of 4 cases with determination of the Mic values. Scand J Infect Dis 1996;28(3):313-6
234. Horstmann M, Kroschke G, Stockschläder M, Betker R, Krüger W, Erttmann R, Kabisch H, Zander A. Early toxicity of intensified conditioning with etoposide combined with total body irradiation/cyclophosphamide or busulfan/cyclophosphamide in children undergoing autologous or allogeneic bone marrow transplantation. Pediatr Hematol Oncol 1996 Jan-Feb;13(1):45-53
235. Hassan HT, Zander A. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Acta Haematol 1996;95(3-4):257-62
236. Zeller W, Hesse I, Dürken M, Stockschläder M, Krüger W, Peters SO, Walter TA, Greenshaw C, Kabisch H, Zander AR. Increasing the yield of harvested bone marrow cells by raising room temperature during marrow collection. Exp Hematol 1995 Dec;23(14):1527-9
237. Stockschläder M, Löliger C, Krüger W, Zeller W, Heyll A, Schonrock-Nabulsi P, Zander A. Transplantation of allogeneic rhG-CSF mobilized peripheral CD34+ cells from an HLA-identical unrelated donor. Bone Marrow Transplant 1995 Nov;16(5):719-22
238. Drize N, Chertkov J, Zander A. Hematopoietic progenitor cell mobilization into the peripheral blood of mice using a combination of recombinant rat stem cell factor (rrSCF) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Exp Hematol 1995 Oct;23(11):1180-6
239. Chukhlovin A, Dahm-Daphi J, Gercken G, Zander AR, Dikomey E. Comparative studies of induction and repair of DNA double-strand breaks in X-irradiated alveolar macrophages and resting peripheral blood lymphocytes using constant-field gel electrophoresis. Int J Radiat Biol 1995 Aug;68(2):163-8
240. Horstmann M, Stockschläder M, Krüger W, Hoffknecht M, Betker R, Kabisch H, Zander A. Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results. Ann Hematol 1995 Aug;71(2):77-81
241. Grimm J, Zeller W, Zander AR. Separation and characterization of mobilized and unmobilized peripheral blood progenitor cells by counterflow centrifugal elutriation. Exp Hematol 1995 Jun;23(6):535-44
242. Peters SO, Stockschläder M, Hegewisch-Becker S, Krüger W, Weh HJ, Hossfeld DK, Zander AR. Infusion of tumor-contaminated bone marrow for autologous rescue after high-dose therapy leading to long-term remission in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1995 May;15(5):783-4
243. Dürken M, Agbenu J, Finckh B, Hübner C, Pichlmeier U, Zeller W, Winkler K, Zander A, Kohlschütter A. Deteriorating free radical-trapping capacity and antioxidant status in plasma during bone marrow transplantation. Bone Marrow Transplant 1995 May;15(5):757-62
244. Stockschläder M, Krüger W, Kroschke G, Zeller W, Hoffknecht M, Loliger C, Kabisch H, Zander A. Use of cryopreserved bone marrow in allogeneic bone marrow transplantation. Bone Marrow Transplant 1995 Apr;15(4):569-72
245. Horstmann M, Stockschläder M, Kabisch H, Zander A. Cyclophosphamide / antithymocyte globulin conditioning of patients with severe aplastic anemia transplanted with bone marrow from HLA-identical related donors. Blood 1995 Mar 1;85(5):1404-5
246. Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H, Fauser AA, Kolb HJ, Zumsprekel A, Martin A, Hecht T. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995 Feb;15(2):261-6
247. Krüger WH, Berger C, Mross KB, Bewermeier P, Pichlmeier U, Stockschläder M, Schleimer B, Zander AR. Inhibition of CFU-C growth by VP-16 containing plasma samples obtained from patients after conditioning therapy for bone marrow transplantation. Bone Marrow Transplant 1995 Jan;15(1):9-15
248. Mross K, Bewermeier P, Krüger W, Stockschläder M, Zander A, Hossfeld DK. Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies. J Clin Oncol 1994 Jul;12(7):1468-74
249. Dimopoulos MA, Yau JC, Huan SD, Jagannath S, Spitzer G, Spinolo JA, Zagars GK, LeMaistre CF, Dicke KA, Zander AR. Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation. Am J Hematol 1994 Jun;46(2):82-6
250. Mross K, Bewermeier P, Reifke J, Krüger W, Stockschläder M, Zander A, Hossfeld DK. Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion. Bone Marrow Transplant 1994 Apr;13(4):423-30
251. Stockschläder M, Kalhs P, Peters S, Zeller W, Krüger W, Kabisch H, Lechner K, Zander A. Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1993 Oct;12(4):357-62
252. Drize N, Gan O, Zander A. Effect of recombinant human granulocyte colony-stimulating factor treatment of mice on spleen colony-forming unit number and self-renewal capacity. Exp Hematol 1993 Aug;21(9):1289-93
253. Hegewisch-Becker S, Fliegner M, Tsuruo T, Zander A, Zeller W, Hossfeld DK. P-glycoprotein expression in normal and reactive bone marrows. Br J Cancer 1993 Mar;67(3):430-5
254. Peters SO, Stockschlader M, Zeller W, Mross K, Durken M, Kruger W, Zander AR. Monoclonal gammopathy of unknown significance in a bone marrow donor. Ann Hematol 1993 Feb;66(2):93-5
255. Kapaun P, Kabisch H, Held KR, Walter TA, Hegewisch S, Zander AR. Atypical chronic myelogenous leukemia in a patient with trisomy 8 mosaicism syndrome. Ann Hematol 1993 Jan;66(1):57-8
256. Zeller W, von Stieglitz J, Dominka T, Kunde C, Cassens U, Zander AR. Mobilization of blood stem cells using G-CSF without preceding chemotherapy. Beitr Infusionsther 1993;31:118-23
257. Kalhs P, Lechner K, Stockschlader M, Kruger W, Peters S, Zander A. Pentoxifylline did not prevent transplant-related toxicity in 31 consecutive allogeneic bone marrow transplant recipients. Blood 1992 Nov 15;80(10):2683-4
258. Spinolo JA, Yau JC, Dicke KA, Scott E, Jagannath S, Horwitz LJ, Spitzer G, Zander AR. Second bone marrow transplants for relapsed leukemia. Cancer 1992 Jan 15;69(2):405-9
259. Krüger W, Stockschläder M, Zander AR. Transmission of rotavirus diarrhea in a bone marrow transplantation unit by a hospital worker. Bone Marrow Transplant 1991 Dec;8(6):507-8
260. Davis BR, Schwartz DH, Marx JC, Johnson CE, Berry JM, Lyding J, Merigan TC, Zander A. Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo. J Virol 1991 Apr;65(4):1985-90
261. Zander AR, Lyding J, Bielack S. Transplantation with blood stem cells. Blood Cells 1991;17(2):301-9
262. Spinolo JA, Dicke KA, Horwitz LJ, Jagannath S, McCredie K, Estey E, Kantarjian H, Zander AR, Keating M, Spitzer G. High-dose chemotherapy and unpurged autologous bone marrow transplantation for acute leukemia in second or subsequent remission. Cancer 1990 Aug 15;66(4):619-26
263. Spinolo JA, Dicke KA, Horwitz LJ, Jagannath S, Zander AR, Auber ML, Spitzer G. Double intensification with amsacrine/high dose ara-C and high dose chemotherapy with autologous bone marrow transplantation produces durable remissions in acute myelogenous leukemia. Bone Marrow Transplant 1990 Feb;5(2):111-8
264. Cockerill KJ, Lyding J, Zander AR. Red cell aplasia due to host type isohemagglutinins with exuberant red cell progenitor production of donor type in an ABO-mismatched allogeneic bone marrow transplant recipient. Eur J Haematol 1989 Sep;43(3):195-200
265. Horwitz LJ, Kantarjian HM, Jagannath S, Keating MJ, McCredie KB, Spitzer G, Vellekoop L, Zander AR, Dicke KA. Piperazinedione plus total body irradiation: an alternative preparative regimen for allogeneic bone marrow transplantation in advanced phases of chronic myelogenous leukemia. Bone Marrow Transplant 1989 Jan;4(1):101-5
266. Zander AR, Keating M, Dicke K, Dixon D, Pierce S, Jagannath S, Peters L, Horwitz L, Cockerill K, Spitzer G, et al. A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. J Clin Oncol 1988 Oct;6(10):1548-57
267. Beran M, Zander AR, Andersson BS, McCredie KB. Regrowth of granulocyte-macrophage progenitor cells (GM-CFC) in suspension cultures of bone marrow depleted of GM-CFC with 4-hydroperoxycyclophosphamide (4-HC). Eur J Haematol 1987 Aug;39(2):118-24
268. Beran M, Zander AR. Critical issues in autologous bone marrow transplantation in adult acute leukemia. Eur J Haematol 1987 Aug;39(2):97-117
269. Zander AR, Culbert S, Jagannath S, Spitzer G, Keating M, Larry N, Cockerill K, Hester J, Horwitz L, Vellekoop L, et al. High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia. Cancer 1987 Mar 15;59(6):1083-6
270. Cabanillas F, Pathak S, Zander A, Goodacre A, Katz R, Sneige N, Trujillo J, Cork A, Manning J, Butler JJ. Monosomy 21, partial duplication of chromosome 11, and structural abnormality of chromosome 1q21 in a case of lymphoma developing in a transplant recipient: characteristic abnormalities of secondary lymphoma? Cancer Genet Cytogenet 1987 Jan;24(1):7-10
271. Zander AR, Cockerill KJ. Autologous transplantation with circulating hemopoietic stem cells. J Clin Apheresis 1987;3(4):191-201
272. Leventon GS, Kulkarni SS, White RA, Zander AR. Enhanced recovery of gut-associated lymphoid tissue by infusion of buffy coat cells and gut leukocytes in the murine syngeneic bone marrow transplantation model. Blood 1986 Nov;68(5):1003-7
273. Vellekoop L, Jagannath S, Spitzer G, Zander AR, Horwitz LJ, Keating M, McCredie KB, Dicke KA. High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse. Am J Clin Oncol 1986 Aug;9(4):307-10
274. Blaauw A, Spitzer G, Dicke K, Drewinko B, Vellekoop L, Zander A. Potential drugs for elimination of acute lymphatic leukemia cells from autologous bone marrow. Exp Hematol 1986 Aug;14(7):683-8
275. Armitage JO, Jagannath S, Spitzer G, Bierman P, Kessinger A, Kumar P, Cabanillas F, Zander A, Vellekoop L, Dicke KA. High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma. Eur J Cancer Clin Oncol 1986 Jul;22(7):871-7
276. Spitzer G, Jagannath S, Dicke KA, Armitage J, Zander AR, Vellekoop L, Horwitz L, Cabanillas F, Zagars GK, Velasquez WS. High-dose melphalan and total body irradiation with bone marrow transplantation for refractory malignancies. Eur J Cancer Clin Oncol 1986 Jun;22(6):677-84
277. Vellekoop L, Zander AR, Kantarjian HM, Jagannath S, Hester JP, Trujillo J, McCredie KB, Zagars G, Spitzer G, Dicke KA. Piperazinedione, total body irradiation, and autologous bone marrow transplantation in chronic myelogenous leukemia. J Clin Oncol 1986 Jun;4(6):906-11
278. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986 May;67(5):1298-301
279. Jagannath S, Dicke KA, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekoop L, Zander AR, Spitzer G. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986 Feb;104(2):163-8
280. Yau JC, Chow HS, Kulkarni SS, Huynh LT, Zander AR. Regeneration of T lymphocytes from human bone marrow cells after depletion with methylprednisolone. J Clin Lab Immunol 1986 Jan;19(1):15-8
281. Yau JC, Zander AR, Srigley JR, Verm RA, Stroehlein JR, Korinek JK, Vellekoop L, Dicke KA. Chronic graft-versus-host disease complicated by micronodular cirrhosis and esophageal varices. Transplantation 1986 Jan;41(1):129-30
282. Spitzer G, Farha P, Valdivieso M, Dicke K, Zander A, Vellekoop L, Murphy WK, Dhingra HM, Umsawasdi T, Chiuten D, et al. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. J Clin Oncol 1986 Jan;4(1):4-13
283. Arden KC, Pathak S, Frankel LS, Zander A. Ag-NOR staining in human chromosomes: differential staining in normal and leukemic bone-marrow samples. Int J Cancer 1985 Dec 15;36(6):647-9
284. Kulkarni SS, Leventon GS, Huynh L, Chow H, Dicke KA, Zander AR. Effect of pretreatment with cyclophosphamide on high-dose toxicity of melphalan in mice. Cancer Res 1985 Nov;45(11 Pt 1):5431-5
285. Zander AR, Dicke KA, Keating M, Vellekoop L, Culbert S, Spitzer G, Kanojia M, Jagannath S, Schell S, Hester J, et al. Allogeneic bone marrow transplantation for acute leukemia refractory to induction chemotherapy. Cancer 1985 Sep 15;56(6):1374-9
286. Zander AR, Reuben JM, Johnston D, Vellekoop L, Dicke KA, Yau JC, Hersh EM. Immune recovery following allogeneic bone marrow transplantation. Transplantation 1985 Aug;40(2):177-83
287. Dicke KA, Vellekoop L, Zander A, Jagannath S, Poynton C, Lichtiger B, Verma DS, Spitzer G. Autologous bone marrow transplantation in acute leukemia. Surv Synth Pathol Res 1985;4(1):84-96
288. Ajani JA, Blaauw AA, Spitzer G, Baker FL, Tomasovic B, Umbach G, Thielvoldt D, Zander AR, Dicke KA. Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro. Exp Hematol 1985;13 Suppl 16:95-100
289. Hall RR, Anagnostou A, Kanojia M, Zander A. Pneumatosis intestinalis associated with graft-versus-host disease of the intestinal tract. Transplant Proc 1984 Dec;16(6):1666-8
290. Kulkarni SS, Bhateley DC, Zander AR, Van Buren CT, Rudolph FB, Dicke KA, Kulkarni AD. Functional impairment of T-lymphocytes in mouse radiation chimeras by a nucleotide-free diet. Exp Hematol 1984 Oct;12(9):694-9
291. Spitzer G, Dicke K, Zander AR, Jagannath S, Vellekoop L, Freireich EJ. High-dose chemotherapy with autologous bone marrow transplantation. Cancer 1984 Sep 15; 54(6 Suppl):1216-25
292. Kurzrock R, Zander A, Vellekoop L, Kanojia M, Luna M, Dicke K. Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. Am J Med 1984 Jul;77(1):35-40
293. Zander AR, Dicke KA. Bone marrow transplantation in malignant diseases and aplastic anemia. Tex Med 1984 Jul;80(7):40-2
294. Vellekoop L, Dicke KA, Zander AR, Spitzer G, Verma DS, Keating MM, McCredie KB. Repeated high-dose cyclophosphamide, BCNU and VP-16-213 and autologous bone marrow transplantation in adult acute lymphocytic leukemia in first remission. Eur J Cancer Clin Oncol 1984 May;20(5):593-9
295. Dicke KA, Jagannath S, Spitzer G, Poynton C, Zander A, Vellekoop L, Reading CL, Jehn UW, Tindle S. The role of autologous bone marrow transplantation in various malignancies. Semin Hematol 1984 Apr;21(2):109-22
296. Kanojia MD, Anagnostou AA, Zander AR, Vellekoop L, Spitzer G, Verma DS, Jagannath S, Dicke KA. High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults. Transplantation 1984 Mar;37(3):246-9
297. Kurzrock R, Zander A, Kanojia M, Vellekoop L, Spitzer G, Jagannath S, Schell S, Peters L, Dicke K. Obstructive lung disease after allogeneic bone marrow transplantation. Transplantation 1984 Feb;37(2):156-60
298. Zander AR, Templeton J, Gray KN, Spitzer G, Verma DS, Dicke KA. Mobilization of canine hemopoietic stem cells by pyran copolymer (NSC 46015). Biomed Pharmacother 1984;38(2):107-10
299. Zander AR, Gray KN, Hester JP, Johnston DA, Spitzer G, Raulston GL, McCredie KB, Jardine JH, Wu J, Gleiser C, et al. Rescue by peripheral blood mononuclear cells in dogs from bone marrow failure after total-body irradiation. Transfusion 1984 Jan-Feb;24(1):42-5
300. Farha P, Spitzer G, Valdivieso M, Dicke KA, Zander A, Dhingra HM, Minnhaar G, Vellekoop L, Verma DS, Umsawasdi T, et al. High-dose chemotherapy and autologous bone marrow transplantation for the treatment of small cell lung carcinoma. Cancer 1983 Oct 15;52(8):1351-5
301. Leventon GS, Kulkarni SS, Meistrich ML, Newland JR, Zander AR. Isolation of murine small bowel intraepithelial lymphocytes. J Immunol Methods 1983 Sep 30;63(1):35-44
302. Tannir NM, Spitzer G, Zander AR, Jagannath S, Kanojia M, Vellekoop L, McLaughlin P, Hagemeister FJ, Dicke KA. High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma. Eur J Cancer Clin Oncol 1983 Aug;19(8):1091-6
303. Tannir N, Spitzer G, Schell F, Legha S, Zander A, Blumenschein G. Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer. Cancer Treat Rep 1983 Jun;67(6):599-600
304. Zander AR, Vellekoop L, Dicke KA, Keating MJ, McCredie KB, Legha SS, Spitzer G, Verma D, Bodey GP. High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia. Cancer Treat Rep 1982 Nov;66(11):1991-2
305. Hittelman WN, Vellekoop L, Zander AR, Dicke KA. Premature chromosome condensation studies in human leukemia: 4. Characterization of albumin density fractionations of bone marrow at presentation, remission, and relapse. Blood 1982 Nov;60(5):1203-11
306. Verma DS, Spitzer G, Johnston DA, Beran M, Zander AR, McCredie KB. Monocyte-macrophage modulation of T-lymphocyte-derived colony-stimulating activity elaboration in man. Scand J Haematol 1982 Mar;28(3):254-63
307. Zander AR, Spitzer G, Legha S, Dicke DA, Verma DS, Johnston DA, Vellekoop L, Beran M, Schell F, Minnhaar G, Blumenschein GR, Bodey GP. High-dose AMSA and bone marrow rescue in patients with solid tumors. Cancer Treat Rep 1982 Feb;66(2):385-6
308. Verma DS, Spitzer G, Gutterman JU, Beran M, Zander AR, McCredie KB. Human leukocyte interferon-mediated granulopoietic differentiation arrest and its abrogation by lithium carbonate. Am J Hematol 1982 Feb;12(1):39-46
309. Hersh EV, Murphy SG, Gutterman JU, Morgan J, Quesada J, Zander A, Stewart D. Antibody-dependent cell-mediated cytotoxicity in human cancer: characterization of patient leukocyte activity and treatment effects. Cancer 1982 Jan 15;49(2):251-60
310. Spitzer G, Verma DS, Beran M, Zander AR, McCredie KB, Dicke KA. Human adherent cell contact-mediated modulation of normal myeloid colony formation. J Natl Cancer Inst 1982 Jan;68(1):35-42
311. Verma DS, Johnston DA, Spitzer G, Zander AR, Dicke KA, McCredie KB. The mechanism of lithium carbonate-induced augmentation of colony-stimulating activity elaboration in man. Leuk Res 1982;6(3):349-63
312. Verma DS, Spitzer G, Zander AR, Dicke KA, McCredie KB. Cyclic neutropenia and T lymphocyte suppression of granulopoiesis: abrogation of the neutropenic cycles by lithium carbonate. Leuk Res 1982;6(4):567-76
313. Zander AR, Huynh L, Spitzer G, Verma DS, Dicke KA. Piperazinedione (NSC 135758) and total body irradiation as an ablative bone marrow transplantation regimen in mice. Exp Hematol 1981 Oct;9(9):945-9
314. Keating MJ, McCredie KB, Benjamin RS, Bodey GP, Zander A, Smith TL, Freireich EJ. Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). Blood 1981 Sep;58(3):584-91
315. McKelvey EM, Murphy W, Zander A, Bodey GP. Neocarzinostatin: report of a phase II clinical trial. Cancer Treat Rep 1981 Jul-Aug;65(7-8):699-701
316. Zander AR, Vellekoop L, Spitzer G, Verma DS, Litam J, McCredie KB, Keating M, Hester JP, Dicke KA. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia. Cancer Treat Rep 1981 May-Jun;65(5-6):377-81
317. Blijham G, Spitzer G, Litam J, Zander AR, Verma DS, Vellekoop L, Samuels ML, McCredie KB, Dicke KA. The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support. Eur J Cancer 1981 Apr;17(4):433-41
318. Dicke KA, Vellekoop L, Spitzer G, Zander AR, Schell F, Verma DS. Autologous bone marrow transplantation in neoplasia. Transplant Proc 1981 Mar;13(1 Pt 1):267-9
319. Spitzer G, Verma DS, Beran M, Zander AR, Dicke KA, McCredie KB, Siegel S, Tindle S. Human myeloid leukaemic cell interactions in vitro with normal myeloid colonies. Br J Cancer 1981 Feb;43(2):149-56
320. Verma DS, Spitzer G, Zander AR, McCredie KB, Dicke KA. Prostaglandin E1-mediated augmentation of human granulocyte-macrophage progenitor cell growth in vitro. Leuk Res 1981;5(1):65-71
321. Spitzer G, Verma DS, Beran M, Zander AR, Dicke KA, McCredie KB. Adherent cell inhibition of human leukemic in vitro agar clonal growth by short-term cell-to-cell contact. Blood 1981 Jan;57(1):71-4
322. Quesada JR, Hersh EM, Keating M, Zander A, Hester J. Hairy cell leukemia: clinical effects of the methanol extraction residue (MER) of BCG, lithium carbonate and mononuclear cell-enriched leukocyte transfusions. : Leuk Res 1981;5(6):463-76
323. Litam JP, Dail DH, Spitzer G, Vellekoop L, Verma DS, Zander AR, Dicke KA. Early pulmonary toxicity after administration of high-dose BCNU. Cancer Treat Rep 1981 Jan-Feb;65(1-2):39-44
324. Verma DS, Spitzer G, Zander AR, Gutterman JU, McCredie KB, Dicke KA, Johnston DA. Human leukocyte interferon preparation-mediated block of granulopoietic differentiation in vitro. Exp Hematol 1981 Jan;9(1):63-76
325. Zander AR, Verma DS, Spitzer G, Huynh L, Johnston D, Beran M, Dicke KA. Enhancement of hemopoietic recovery after bone marrow transplantation with the addition of nucleated blood cells in mice. Blood 1980 Dec;56(6):1132-5
326. Spitzer G, Verma DS, Zander A, Beran M, Dicke KA, Siegel S. One-step procedure for human T-lymphocyte colony growth and its regulation by T and B cells, and monocytes. Exp Hematol 1980 Nov;8(10):1241-52
327. Spitzer G, Verma DS, Zander A, Beran M, Dicke KA, Tindle S, Siegel S. Adherent cell-mediated inhibition of human leukemic myelopoiesis. Exp Hematol 1980 Oct;8(9):1146-56
328. Zander AR, Sarpell S, Cunningham B, Hess AD, Johnston DA, Epstein RB. Plasmapheresis as immunotherapeutic modality in the treatment of the canine venereal tumor. Exp Hematol 1980 Oct;8(9): 1123-8
329. Hersh EM, Murphy S, Zander A, Dicke K, Stewart DJ, Toki H, Latreille J. Host defense deficiency in hairy cell leukemia and its correction by leukocyte transfusion. Blood 1980 Sep;56(3):526-33
330. Hersh EM, Patt YZ, Murphy SG, Dicke K, Zander A, Adegbite M, Goldman R. Radiosensitive, thymic hormone-sensitive peripheral blood suppressor cell activity in cancer patients. Cancer Res 1980 Sep;40(9):3134-40
331. Legha SS, Keating MJ, Zander AR, McCredie KB, Bodey GP, Freireich EJ. 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. Ann Intern Med 1980 Jul;93(1):17-21
332. Spitzer G, Dicke KA, Litam J, Verma DS, Zander A, Lanzotti V, Valdivieso M, McCredie KB, Samuels ML. High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors. Cancer 1980 Jun 15;45(12):3075-85
333. Zander AR, Spitzer G, Verma DS, Beran M, Dicke KA. Effect of pyran copolymer on murine hemopoiesis. Exp Hematol 1980 May;8(5):521-6
334. Zander AR, Spitzer G, Verma DS, Ginzbarg S, Dicke KA. Pyran copolymer: effect of molecular weight on stem cell mobilization in mice. Biomedicine 1980 May;33(3):69-72
335. Spitzer G, Verma DS, Fisher R, Zander A, Vellekoop L, Litam J, McCredie KB, Dicke KA. The myeloid progenitor cell--its value in predicting hematopoietic recovery after autologous bone marrow transplantation. Blood 1980 Feb;55(2):317-23
336. Verma DS, Fisher R, Spitzer G, Zander AR, McCredie KB, Dicke KA. Diurnal changes in circulating myeloid progenitor cells in man. Am J Hematol 1980;9(2):185-92
337. Dicke KA, Zander AR, Spitzer G, Verma DS, Peters L, Vellekoop L, Thomson S, Stewart D, McCredie KB. Autologous bone marrow transplantation in relapsed adult acute leukemia. Hamatol Bluttransfus 1980;25:309-20
338. Verma DS, Spitzer G, Zander AR, Beran M, Dicke KA, McCredie KB. The kinetics of colony-stimulating activity elaboration from human bone marrow cells by immunoadjuvants: interactions between light density adherent and nonadherent cells in vitro. Leuk Res 1980;4(4):371-83
339. Zander AR, Hess AD, Epstein RB. Immunosuppressive effects of rabbit anti-canine brain serum. Exp Pathol (Jena) 1980;18(5):310-3
340. Verma DS, Spitzer G, Zander AR, Fisher R, McCredie KB, Dicke KA. The myeloid progenitor cell: a parallel study of subpopulations in human marrow and peripheral blood. Exp Hematol 1980 Jan;8(1):32-43
341. Verma DS, Spitzer G, Zander AR, Beran MA, Dicke KA. Myelopoietic modulation by lithum: in vitro experiments on its mechanisms of action in man. Adv Exp Med Biol 1980;127:111-26
342. Verma DS, Spitzer G, Gutterman JU, Zander AR, McCredie KB, Dicke KA. Human leukocyte interferon preparation blocks granulopoietic differentiation. Blood 1979 Dec;54(6):1423-7
343. Verma DS, Spitzer G, Zander AR, Fisher R, McCredie KB, Dicke KA. T lymphocyte and monocyte-macrophage interaction in colony-stimulating activity elaboration in man. Blood 1979 Dec;54(6):1376-83
344. Zander AR, Verma DS, Spitzer G, Culbert S, Peters L, McCredie K, Dicke KA. Autologous bone marrow transplantation in acute leukemia. Int J Radiat Oncol Biol Phys 1979 Sep;5(9):1709-10
345. Spitzer G, Dicke KA, Verma DS, Zander A, McCredie KB. High-dose BCNU therapy with autologous bone marrow infusion: preliminary observations. Cancer Treat Rep 1979 Aug;63(8):1257-64
346. Dicke KA, Zander A, Spitzer G, Verma DS, Peters L, Vellekoop L, McCredie KB, Hester J. Autologous bone-marrow transplantation in relapsed adult acute leukaemia. Lancet 1979 Mar 10;1(8115):514-7
347. Dicke KA, Spitzer G, Zander AR, Lanzotti VJ, Verma DS, Peters LJ, Valdivieso M, Lotzova E, McCredie KB. Autologous bone marrow transplantation in relapsed adult acute leukemia and solid tumors. Transplant Proc 1979 Mar;11(1):212-4
348. Sarpel SC, Zander AR, Harvath L, Epstein RB. The collection, preservation and function of peripheral blood hematopoietic cells in dogs. Exp Hematol 1979 Feb;7(2):113-20
349. Spitzer G, Dicke KA, Verma DS, Zander A, Litam J, DiStefano A, Lanzotti V. High dose chemotherapy with autologous bone marrow transfusion. Exp Hematol 1979;7 Suppl 5:38-53
350. Verma DS, Spitzer G, Dicke KA, Zander AR, Vellekoop L, Beran M. Myelopoietic enhancement by immunoadjuvants: in vitro studies for their rational use in neutropenic patients. Exp Hematol 1979;7 Suppl 5:228-45
351. Dicke KA, Zander AR, Spitzer G, Verma DS, Peters LJ, Vellekoop L, Thomson S, Stewart D, Hester JP, McCredie KB. Autologous bone marrow transplantation in relapsed adult acute leukemia. Exp Hematol 1979;7 Suppl 5:170-87
352. Zander AR, Dicke KA, Verma D, Ginzbarg S, Spitzer G. Mobilization of murine hemopoietic stem cells (HSC) by Pyran Copolymer. Exp Hematol 1979;7 Suppl 5:116-24
353. Dicke KA, McCredie KB, Spitzer G, Zander A, Peters L, Verma DS, Stewart D, Keating M, Stevens EE. Autologous bone marrow transplantation in patients with adult acute leukemia in relapse. Transplantation 1978 Sep;26(3):169-73
354. Elfenbein GJ, Brogaonkar DS, Bias WB, Burns WH, Saral R, Sensenbrenner LL, Tutschka PJ, Zaczek BS, Zander AR, Epstein RB, Rowley JD, Santos GW.Cytogenetic evidence for recurrence of acute myelogenous leukemia after allogeneic bone marrow transplantation in donor hematopoietic cells. Blood 1978 Sep;52(3):627-36
355. Hess AD, Catchatourian R, Zander AR, Epstein RB.Intralesional Bacillus Calmette-Guerin immunotherapy of canine venereal tumors. Cancer Res 1977 Nov;37(11):3990-4
356. Epstein RB, Zander AR.Granulocyte transfusions in leukopenic dogs. Prog Clin Biol Res 1977;13:227-41
357. Anagnostou A, Zander A, Barone J, Fried W.Mechanism of the increased splenic erythropoiesis in mice treated with estradiol benzoate. J Lab Clin Med 1976 Nov;88(5):700-6
358. Harvath L, Andersen BR, Zander AR, Epstein RB.Combined pre-immunization and granulocyte transfusion therapy for treatment of pseudomonas septicemia in neutropenic dogs. J Lab Clin Med 1976 May;87(5):840-7
359. Zander AR, Boopalam N, Epstein RB. Surface markers on canine lymphocytes. Transplant Proc 1975 Sep;7(3):369-73
